This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our and .
Healthcare
Disappointing year for Roche but restructuring will help maintain strong fiscal position
Melbourne, 18th November 2010 - John Bird, pharmaceutical company analyst at Datamontior, comments on Roche’s plans to cut 6 percent of its global workforce, or 4800 jobs, over the next two years as part of efforts to make annual cost savings of $2.4 billion: “Many Big Pharma companies have restructured in recent times due to…
18 Nov 2010, by Informa InsightsHealthcare
Market development key for testosterone replacement therapy
Melbourne, 17th November 2010 - Despite growing at a compound annual growth rate of more than 24% over the last five years, the testosterone replacement therapy market is severely underdeveloped. This suggests there are great opportunities for pharmaceutical companies in this field, claims independent market analyst, Datamonitor*. The testosterone replacement therapy market, valued at $838m…
17 Nov 2010, by Informa InsightsHealthcare
Can Pfizer rescue hormonal replacement therapy?
Melbourne, 17th November 2010 - In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor*. The value of…
17 Nov 2010, by Informa InsightsEducation
A question of culture as well as structure
IGNORING the entrenched prejudices of further and higher education can lead to divorce. IN 2004, Thames Valley University, a former English polytechnic based in west London, merged with Reading College, a further education institution (or TAFE). The merger was historic, creating England's first dual-sector university. The talk was about providing seamless transition from further to…
1 Nov 2010, by Informa InsightsHealthcare
Pfizer to acquire King Pharmaceuticals for $3.6 billion.
Expert comment from Datamonitor principal analyst Simon King: “The King acquisition represents a small but integral part of a broader diversification strategy that continues to be implemented by Pfizer. This strategy has to date encompassed the multi-billion dollar acquisition of Wyeth but also various in-licensing agreements and a concerted movement into the generics market as…
15 Oct 2010, by Informa InsightsHealthcare
The case for constant innovation in Australian biotech
Melbourne – 12th October 2010 – The sales contribution from internally developed products is expected to decline from $284 billion in 2009 to $274 billion in 2014, by which time the majority of sales will be derived from externally sourced products. Pharma’s continued need to restock pipelines in order to secure future growth—in the face…
12 Oct 2010, by Informa InsightsPlanning & Design | Transport & Logistics
Written interview with the CEO of NSW Business Chamber
We had the opportunity to get an interview with Stephen Cartwright, CEO, NSW Business Chamber, who is nice enough to give us a few minutes of his busy day to fill in some blanks for us! Building and maintaining transport infrastructure is of pivotal importance for the future prosperity of NSW. We had the chance…
11 Oct 2010, by Informa InsightsHealthcare
Asia-Pacific products are in later stages of development compared to other markets
Melbourne – 11th October 2010 – Asia-Pacific products are in later stages of development compared to other markets, but still comprise only 15% of global products in development according to MedTRACK, a market leading database of private and public biomedical companies. The volume of products in development in the Asia-Pacific region still lags behind North…
11 Oct 2010, by Informa InsightsHealthcare
Implications of Nivestim’s approval on the Australian biosimilars market
Melbourne – 6th October 2010 – Biosimilars in Australia: Nivestim approval opens up local filgrastim biosimilars market. Lisette Oversteegen, Lead Analyst, comments: “Although the recent approval of biosimilar filgrastim is a positive development for the Australian industry, the proposed biosimilars pricing regulations may slow uptake”. Compared with Europe, where several biosimilar products of three different…
6 Oct 2010, by Informa InsightsHealthcare
The Australian reimbursement committee is set to consider Novo Nordisk’s type 2 diabetes treatment
Melbourne – 5th October 2010 - Novo Nordisk: swift approval of Victoza for reimbursement is vital to the drug's success. Lisette Oversteegen, Lead Analyst, comments: “For a prescription drug to be commercially successful in Australia, being included on the country's government reimbursement list, the Pharmaceutical Benefits Scheme (PBS) is essential”. In its November meeting, the…
5 Oct 2010, by Informa InsightsInforma Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.
